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taining bone strength [1, 2]. The plasma calcitonin concentration 
is relatively high in infants, and decreases rapidly until adolescence, 
leveling off during adulthood [3]. On average, its concentration is 
higher in men than in women [4, 5]. 
Calcitonin concentration abnormally increases in medullary 
thyroid cancer [6, 7]. A cut-off concentration of 10 pg/mL is most 
commonly used to differentiate between C-cell hyperactivity dis-
eases (including medullary thyroid cancer) and other thyroid dis-
eases [8-10]. In addition, a follow-up of plasma calcitonin concen-
tration after treatment for medullary thyroid cancer is useful for 
monitoring recurrence and predicting patient prognosis [11, 12]. 
The diagnostic utility of plasma calcitonin concentration further 
increases when reviewed in combination with the carcinoembry-
onic antigen (CEA) concentration, RET protooncogene mutations, 
and needle aspiration biopsy ndings [13, 14]. The measurement 
of serum calcitonin level is markedly signicant as it serves as a 
quick and cost-effective method for diagnosing medullary thyroid 
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Background: To date, only a few studies have focused on the standardization of the calcitonin assay, despite the fact that a lack of standardiza-
tion of assays can lead to discrepancy in results. Here, we analyzed the concordance in serum calcitonin test results using three different assays.
Methods: The serum calcitonin levels in 104 residual specimens collected between January and February 2020 were measured using three dif-
ferent systems. The Spearman’s rank correlation coefficients and the slopes and y-intercepts were assessed to derive all possible pairs of analyz-
ers. The agreement of classification according to a clinically relevant cut-off was also evaluated using Cohen’s kappa coefficient. 
Results: The correlation coefficients for Cobas e801 versus LIAISON, Atellica IM-1600 versus LIAISON, and Cobas e801 versus Atellica IM-1600 
were 0.77, 0.63, and 0.95, respectively. The kappa agreement of classification at a cut-off of 10 pg/mL was 0.81, 0.81, and 0.91, respectively. How-
ever, after excluding the data points for concentrations >20 pg/mL, the correlation coefficients decreased to 0.39, 0.22, and 0.90, respectively.
Conclusions: Despite acceptable correlations for the full analytical measuring range, we observed limited correlations at low concentrations, 
especially around the clinical decision threshold. Therefore, continuous joint efforts by all stakeholders are essential for standardizing calcitonin 
assays. 
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cancer [6, 15-19]. Serum calcitonin concentration testing, like most 
tests conducted in modern clinical laboratories, is becoming in-
creasingly advanced and automated [5, 9, 20-22].
However, standardization and harmonization of calcitonin mea-
surements using various assays have not been achieved to date. 
Only few studies have evaluated the equivalence of different cal-
citonin assays [5, 23]. In this context, we compared the serum cal-
citonin levels measured using three different automated immuno-
chemical analyzers, namely the LIAISON (Diasorin, Saluggia, It-
aly), Atellica IM 1600 (Siemens Healthcare Diagnostics Inc., New 
York, USA), and Cobas e801 (Roche Diagnostics GmbH, Mannheim, 
Germany), to evaluate the equivalence of the test results and de-
termine whether the current clinical calcitonin cut-offs apply to 
the available calcitonin immunoassays used in clinical laboratories.
MATERIALS AND METHODS
1. Specimen collection and calcitonin measurement
From January to February 2020, 104 serum samples were re-
ferred to the laboratory of Severance Hospital for routine calcito-
nin measurement. Immediately after completion of the routine 
test, each sample was aliquoted into three tubes and stored at -70˚C 
until the calcitonin levels were measured using the three different 
assays. The aliquots were thawed between 20-23˚C on the same 
day and measured using three analyzers, namely the LIAISON, 
Atellica IM 1600, and Cobas e801 systems without any time inter-
val (Table 1). This study protocol was reviewed and approved by 
the Institutional Review Board of Severance Hospital in Seoul, 
Korea (IRB No. 2019-3377-001).
2. Comparison of the methods
The methods were compared according to the Clinical and 
Laboratory Standards Institute (CLSI) guideline EP09c-ED3 [24]. 
As an established reference method was not available, we per-
formed pairwise comparisons of the results obtained using the 
LIAISON, Atellica IM 1600, and Cobas e801 systems. After con-
ducting an initial analysis with all data points, we excluded the 
data points for concentrations >20 pg/mL and repeated the anal-
ysis to evaluate the agreement of the measured values near the 
clinically signicant cut-off value of 10 pg/mL.
3. Concordance of the calcitonin level classification
The calcitonin level of each subject was classied as normal or 
high based on a clinically meaningful cut-off of 10 pg/mL [8-10]. 
The agreement of the classication among the three methods, ex-
pressed as Cohen’s kappa and percentage of observed agreement, 
was evaluated.
4. Statistical analysis
We performed statistical analysis and presented the results as 
graphs using Analyse-it (v2.30, Analyse-it Software Ltd, Leeds, UK). 
The relationships among the calcitonin assays were evaluated by 
Spearman correlation analysis. The slope and y-intercepts for the 
results obtained using each instrument were determined by per-
forming the Passing–Bablok regression analysis to investigate the 
equivalence between the pairs of instruments. Cohen’s kappa co-
efcient was also calculated to analyze the classication concor-
dance.
RESULTS
1. Comparison of three different analyzers
The calcitonin values measured by the LIAISON analyzer were 
mainly distributed between <1.0 and >2,000 pg/mL. Fifty-six of 
the 104 samples (53.3%) had values exceeding the clinically mean-
ingful cut-off (10 pg/mL). The Cobas e801 analyzer showed posi-




Assay principle AMR (pg/mL) Traceability






Atellica IM Calcitonin Assay Biotinylated antibody CLIA 1.89–2,000 WHO
Reference Standard 89/620
Roche Diagnostics Cobas e801 Elecsys Calcitonin Assay Biotinylated antibody ECLIA 0.5–2,000 WHO
Reference Standard 89/620
Abbreviations: AMR, analytical measurement range; CLIA, chemiluminescence immunoassay; ECLIA, electrochemiluminescence immunoassay.
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tive bias compared with the LIAISON analyzer, with a slope of 
1.23; y-intercept, -0.94; and R, 0.77 (Fig. 1). The Atellica IM 1600 
analyzer also showed a positive bias compared with the LIAISON 
analyzer, with a slope of 1.14; y-intercept, 1.18; and R, 0.63. Com-
parison of the Atellica IM 1600 analyzer with the Cobas e801 ana-
lyzer showed a slope of 1.05, y-intercept of 2.27, and R of 0.95, in-
dicating a relatively smaller bias and a higher correlation than that 
of the other two pairs. 
Fig. 1. Passing–Bablok regression and bias plots for all data points. Results obtained using the Cobas e801 analyzer compared to those obtained us-
ing the LIAISON analyzer (upper left), results obtained using the Atellica IM1600 analyzer compared to those obtained using the LIAISON analyzer 
(middle left), and results obtained using the Atellica IM1600 analyzer compared with those obtained using the Cobas e801 analyzer (lower left) 
were plotted with the Passing–Bablok regression and identity lines. P-values for linearity test are also indicated. The corresponding relative bias 
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2.  Correlation analysis of the data points for 
concentrations below 20 pg/mL
We conducted an additional analysis using only the data points 
for concentration <20 pg/mL to assess the concordance among 
the measured values near the clinically signicant cut-off value of 
10 pg/mL, which is commonly used for differentiating possible 
thyroid cancers from benign conditions. The exclusion of points 
for concentrations >20 pg/mL had a substantial impact on the 
slopes and intercepts during pairwise comparisons of the instru-
ments. The Cobas e801 analyzer showed a negative bias compared 
Fig. 2. Passing–Bablok regression and bias plots excluding the data points for concentrations >20 pg/mL. Results obtained using the Cobas e801 
analyzer compared to those obtained using the LIAISON analyzer (upper left), results obtained using the Atellica IM1600 compared to those using 
the LIAISON analyzer (middle left), and results obtained using the Atellica IM1600 analyzer compared to those obtained using the Cobas e801 an-
alyzer (lower left) were plotted with the Passing–Bablok regression and identity lines. Only data points for concentrations <20 pg/mL were includ-
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with the LIAISON analyzer, with a slope of 0.86; y-intercept, 0.07; 
and R, 0.39 (Fig. 2). The Atellica IM 1600 analyzer also showed 
negative bias compared with the LIAISON analyzer, with a slope 
of 0.88; y-intercept, 2.31; and R, 0.22. Comparison of the Atellica 
IM 1600 analyzer with the Cobas e801 analyzer revealed a slope 
of 1.27; y-intercept, 1.74; and R, 0.90, indicating a much higher cor-
relation than those noted for the other two pairs. The rst two pairs 
under consideration showed signicantly decreased correlation 
coefcients after excluding the data points for concentrations >20 
pg/mL. We next calculated the relative differences at a critical value 
of 10 pg/mL between pairs of analyzers (Table 2). Compared to 
LIAISON’s result of 10 pg/mL, Cobas e801 showed a value of 8.63 
pg/mL (95% condence interval [CI]; 5.61 to 10.25 pg/mL) and a 
relative difference of -13.66% (95% CI; -43.95% to 2.49%). Similarly, 
Atellica IM 1600 showed a value of 11.15 pg/mL (95% CI; 8.01 to 
13.43 pg/mL) and a relative difference of 11.48% (95% CI; -19.92% 
to 34.33%) over LIAISON. When Atellica IM 1600 was compared 
to Cobas e801, Atellica IM 1600 showed a value of 14.41 pg/mL 
(95% CI; 13.37 to 16.53 pg/mL) and the relative difference was 44.07% 
(95% CI; 33.67% to 65.31%) at 10 pg/mL as measured by Cobas e801.
3.  Categorical concordance rate based on the cut off 
level of 10 pg/mL
We also assessed the effects of these systemic biases on the clin-
ical interpretation of calcitonin levels. The calcitonin levels obtained 
using each instrument were categorized based on the commonly 
used clinical decision point, namely ≤10 pg/mL or >10 pg/mL. 
Using the Cobas e801 analyzer, the calcitonin levels in 30 of the 
104 (28.8%) samples exceeded 10 pg/mL; the results of all 30 (100.0%) 
samples matched the results obtained using the LIAISON analyzer 
(Table 3). Moreover, 74 of the 104 (71.2%) samples showed calcito-
nin levels ≤10 pg/mL; the results of 65 of these 74 (87.8%) matched 
the results obtained using the LIAISON analyzer. In summary, for 
9 samples, only the LIAISON analyzer provided calcitonin con-
centration measurements >10 pg/mL, and only the LIAISON ana-
lyzer did not detect calcitonin levels ≤10 pg/mL in any sample. 
Cohen’s kappa, used to assess classication concordance, was 
0.81. Using the Atellica IM 1600 analyzer, calcitonin levels in 34 of 
the 104 (32.7%) samples exceeded 10 pg/mL; the results of 32 of 
34 (94.1%) matched the results obtained using the LIAISON ana-
lyzer. A total of 70 of the 104 (67.3%) samples had calcitonin levels 
≤10 pg/mL; the results of 63 (90.0%) of these samples mat ched 
the results obtained using the LIAISON analyzer. For 7 samples, 
only the LIAISON analyzer provided calcitonin concentration 
measurements >10 pg/mL; however, only 2 samples had calcito-
nin levels ≤10 pg/mL as detected using the LIAISON analyzer. 
Cohen’s kappa was 0.81. Comparison of the Atellica IM 1600 ana-
lyzer with the Cobas e801 analyzer revealed matching results of 
calcitonin levels >10 pg/mL for 30 of the 34 (88.2%) samples and 
of calcitonin levels ≤10 pg/mL for all 70 of 70 (100.0%) samples. 
Cohen’s kappa was 0.91. 
To directly show the discordant results, the overall calcitonin 
Table 2. Predicted calcitonin concentrations and relative differences at 10 pg/mL calculated by the Passing–Bablok regression analysis with data 
points for concentrations <20 pg/mL
Compared methods (Y to X) N Predicted Y (95% CI) Relative difference, % (95% CI)
Cobas e801 modular analyzer to LIAISON analyzer 76  8.63 (5.61 to 10.25) -13.66 (-43.95 to 2.49)
Atellica IM 1600 analyzer to LIAISON analyzer 76 11.15 (8.01 to 13.43) 11.48 (-19.92 to 34.33)
Atellica IM 1600 analyzer to Cobas e801 modular analyzer 76  14.41 (13.37 to 16.53)  44.07 (33.67 to 65.31)
Abbreviation: CI, confidence interval.
Table 3. Agreement of calcitonin concentration classification based 
on the clinical decision point
A. Cobas e801 system versus LIAISON system
LIAISON, pg/mL
≤10 >10
Cobas, pg/mL ≤10 65   9
>10   0 30
B. Atellica IM-1600 system versus LIAISON system
LIAISON, pg/mL
≤10 >10
Atellica, pg/mL ≤10 63   7
>10   2 32
C. Atellica IM-1600 system versus Cobas e801 system
Cobas, pg/mL
≤10 >10
Atellica, pg/mL ≤10 70   0
>10   4 30
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concentration values <30 pg/mL obtained using the three differ-
ent instruments were presented in ascending order in a single 
chart (Fig. 3). The three results for each sample obtained using the 
three different analyzers are presented on a single vertical line. 
The results obtained using the different analyzers are indicated by 
hollow markers, whereas the solid markers indicate discordance 
in the concentration category based on a cut-off of 10 pg/mL. The 
11 samples showing discordant results include 7 samples with cal-
citonin concentrations >10 pg/mL measured using only the LIAI-
SON analyzer, 2 samples with calcitonin concentrations >10 pg/
mL measured using only the Atellica IM 1600 analyzer, and 2 
samples with calcitonin concentration >10 pg/mL measured us-
ing both the LIAISON and Atellica IM 1600 analyzers.
DISCUSSION
Previously, the serum calcitonin levels were primarily measured 
using a radioimmunoassay. However, the differences in assay spec-
icity and sensitivity, matrix-related and nonspecic serum effects, 
and heterogeneity in the circulating calcitonin levels contributed 
to contradicting results and discrepancies in the calcitonin con-
centrations measured using different assays. In modern clinical 
laboratories, several highly sensitive two-site immunometric meth-
ods, including chemiluminescence immunoassay (CLIA) are used. 
However, the methods for measuring calcitonin levels are not cur-
rently fully standardized [25]. Therefore, we conducted direct com-
parisons of the currently available instruments used for calcitonin 
measurement to empirically demonstrate the level of harmoniza-
tion in clinical laboratories.
Initially, when all data points were included in the comparison, 
both the Cobas e801 and Atellica IM 1600 analyzers showed lim-
ited positive bias compared with the LIAISON analyzer, with ac-
ceptable correlation coefcients for both comparisons. The com-
parison of the Atellica system with the Cobas indicated better cor-
relation and non-signicant bias. Similarly, the bias noted upon 
comparing the Cobas and the Atellica with the LIAISON analyzer 
led to clinically signicant differences in the interpretation of the 
calcitonin levels. Based on the clinical cut-off of 10 pg/mL, of the 
39 samples determined positive by LIAISON analyzer, 9 samples 
were determined negative by Cobas analyzer and 7 samples were 
Fig. 3. Scatter plot showing calcitonin concentrations measured using all three analyzers. Data points for the calcitonin concentrations <50 pg/mL 
measured using the three analyzers were plotted in the order of increasing average concentrations. The discordance between the interpretive cate-

























송준협 외: Comparison of Calcitonin Immunoassays
https://doi.org/10.47429/lmo.2021.11.4.235 www.labmedonline.org   241
determined negative by the Atellica analyzer, thereby revealing 
substantial discordance with the results from LIAISON system. Af-
ter excluding the data points for concentrations >20 pg/mL, the 
discordance between the measured values around 10 pg/mL was 
elucidated. We observed some aberrant high concentrations when 
using the LIAISON analyzer compared to the other two analyzers. 
Comparison of the Atellica to the Cobas analyzer showed relatively 
high correlation, although some positive bias was observed. Based 
on the clinical cut-off of 10 pg/mL, the calcitonin levels of 39 of 
the 104 samples (37.5%) were above the threshold level when us-
ing the LIAISON analyzer, while the calcitonin levels of 9 of the 
39 samples were below the threshold level when using the Cobas 
analyzer, revealing signicant discordance with the results obtained 
using the LIAISON analyzer. Similarly, the calcitonin levels of 7 of 
the 39 samples were below the threshold level when using the At-
ellica analyzer, which also showed substantial discordance with 
the results obtained using the LIAISON system. After excluding 
the data points for concentrations >20 pg/mL (to elucidate the 
discordance between the values measured around the 10 pg/mL 
level), the results obtained using the Cobas e801 and Atellica IM 
1600 analyzers showed weak correlations with those obtained us-
ing the LIAISON analyzer. The discordance in the calcitonin con-
centration measured near 10 pg/mL seemed to be the major con-
tributor to this weak correlation. We observed some aberrantly 
high concentrations using the LIAISON analyzer compared to 
concentrations obtained for identical samples analyzed using the 
other analyzers. Comparison of the Atellica to the Cobas analyzer 
revealed higher correlation, although some positive bias was ob-
served.
The Royal College of Pathologists of Australasia suggests an ac-
ceptable difference ±2 pg/mL calcitonin level for concentrations 
that are the same as, or less than 20 pg/mL and ±10% for concen-
trations above 20 pg/mL [26]. The allowable difference band was 
drawn on relative bias plots in Figs. 1 and 2. When all the data 
points were analyzed, Cobas e801 and Atellica IM1600 showed 
some positive bias over LIAISON between 20 pg/mL and 600 pg/
mL, while for data points below 20 pg/mL, the two analyzers as-
signed a profoundly lower value for some samples than the LIAI-
SON. The relative difference for these samples, even exceeding 
-100% sometimes, may have critically attributed to the weak cor-
relation between LIAISON and the other two analyzers. For these 
samples, factors involved in pre-analytical or analytical phases 
could be considered as causes of the discrepancy. When the sam-
ples were being measured, there were no cases of recognized he-
molysis, icterus, or lipidemia. Moreover, the principles of the three 
assays invariably resort to mouse anti-hCT (human calcitonin) an-
tibody, albeit minor variations exist among reagent compositions. 
Characteristic reagent components of the three assays are indi-
cated in Table 1. LIAISON assay included a small amount of poly-
clonal mouse IgG in its assay buffer to prevent the interference 
from heterophilic antibody. However, the Cobas and Atellica as-
says used a biotinylated antibody. This may result in interference 
from any intake of a biotin substance. All these minor differences 
among the assays might attribute to the discordance to some ex-
tent.
Due to the lack of a reference method for measuring the calci-
tonin concentration, we cannot conclude that results obtained us-
ing one of these analyzers may be closer to the actual values than 
those obtained using the other analyzers. However, because there 
were some aberrant high concentrations around 10 pg/mL when 
using the LIAISON analyzer in our study, we attempted to verify 
whether false-positive results using this analyzer were reported 
previously. Our results may be more informative when reviewed 
in combination with those reported in previous studies [5, 23]. Bie-
glmayer et al. [23] compared four calcitonin assays: the rst ver-
sion of a CLIA from LIAISON (Stillwater, MN, USA), a CLIA from 
Nichols Institute Diagnostics (San Juan Capistrano, CA, USA), a 
CLIA from Diagnostic Products Corporation (Los Angeles, CA, 
USA), and an immunoradiometric assay from Scantibodies (San-
tee, CA, USA). Comparisons of these assays revealed implausible 
detection of calcitonin levels in thyroidectomized patients using 
the LIAISON system and substantial discordance in the measured 
concentrations among all assays assessed, especially at low calci-
tonin levels. Cavalier et al. [5] compared the LIAISON Calcitonin 
II-gen to the cisbio h-CT (CIS bio international, Gif-sur-Yvette, France) 
to validate the analytical performance of the second-generation 
LIAISON calcitonin assay. The measurement of serum calcitonin 
concentrations in 250 consecutive patients showed no signicant 
systematic bias or signicant differences, as noted by the Wilcoxon 
test. They concluded that the specicity of the new version of the 
LIAISON analyzer was markedly improved, although 1 of the 14 
thyroidectomized patients showed detectable calcitonin concen-
trations. 
Currently, there is no consensus on the reference method for 
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calcitonin measurement. To standardize the calcitonin assay, the 
World Health Organization (WHO) established an international 
reference preparation, IRR 70/234, which was replaced by the IS 
89/620 standard. All three assays addressed in this study are trace-
able to this IS 89/620 standard. However, this standard is not com-
mutable (that is, not proven to be equivalent for representative au-
thentic clinical samples) for any specic assay [27]. Therefore, the 
possibility of signicant inter-assay differences could not be disre-
garded, although most assays are currently calibrated to a com-
mon international reference standard. In addition, it remains un-
certain whether the current clinical calcitonin cut-off applies to all 
available calcitonin immunoassays or if monitoring using different 
methods is clinically reliable when patients are transferred between 
healthcare facilities. There is a scarcity of studies on the concor-
dance among various calcitonin test methods. The results of the 
present study indicated the differences in the measured calcitonin 
values for each of the three analyzers, especially at low values near 
the clinical cut-off. These differences are probably attributable to 
the use of different calibrators among the manufacturers, which is 
an inevitable challenge as commutable reference material is not 
available. Therefore, joint efforts by the expert scientic commu-
nity, manufacturers, and regulatory organizations are warranted 
to establish a reference method and commutable reference mate-
rial for improved standardization and harmonization of the calci-
tonin assays.
Discordant results for calcitonin levels can lead to misclassica-
tion of patients and unnecessary additional examinations or de-
layed diagnosis of serious disease. Due to the high sensitivity and 
specicity of calcitonin to medullary thyroid cancer, routine calci-
tonin measurements are performed in many countries, including 
major parts of Europe [16]. In patients with elevated basal serum 
calcitonin levels >10 pg/mL, pentagastrin stimulation testing is 
performed to distinguish among the false-positive ndings and to 
more accurately estimate the possibility of medullary thyroid can-
cer [28]. Stimulated calcitonin concentrations >200 pg/mL suggest 
medullary thyroid cancer, which requires thyroidectomy. With re-
spect to the impact of early diagnosis, a study on the screening of 
10,864 patients reported elevated calcitonin levels in 44 patients, 
all conrmed to have medullary thyroid cancer based on penta-
gastrin-stimulated calcitonin tests. Among these patients, 59% 
achieved complete remission compared to 2.7% of patients with 
medullary thyroid cancer before the implementation of calcitonin 
screening [17]. A common cut-off of 10 pg/mL is conventionally 
used for the initial screening of C-cell hyperplastic conditions [8-
10]. However, additional studies are needed to achieve a sophisti-
cated and evidence-based consensus on new criteria considering 
the inter-method variability. Sex-specic cut-offs should also be 
considered as the reference intervals of normal calcitonin levels 
for women and men signicantly differ [4, 5, 29]. In the current sit-
uation where there is an apparent lack of harmonization among 
the calcitonin measurement methods, the same instrument should 
be used to obtain the follow-up calcitonin concentration for a pa-
tient. Moreover, it is recommended that each laboratory use method-
specic reference interval rather than universal cut-off for clinical 
decision.
This study had several limitations. First, we compared only three 
assays that use the CLIA method. Thus, further studies evaluating 
the equivalence among more assays using different test principles 
are warranted. Second, as the clinical information of patients was 
not available, we could not accurately identify the assay that pro-
vided clinically reliable results when there were discrepancies in 
the classication based on concentration.
The results of this study showed that, although three automated 
calcitonin immunoassays showed acceptable correlations for the 
full analytical measurement range, the correlation and agreement 
were limited at low concentration ranges, especially at the clinical 
decision threshold (10 pg/mL). Hence, continuous joint efforts by 
the expert scientic community, manufacturers, and regulatory 
organizations are imperative for improved standardization and 
harmonization of the calcitonin tests to avoid unnecessary and 
costly additional testing or absence of testing that may lead to a 
missed diagnosis of cancer. A single instrument should be consis-
tently used when following-up a patient to avoid the effect of sys-
temic bias among the instruments.
요 약
배경: 임상 검사실에서 사용하는 여러 검사법 간에 표준화가 불충
분할 경우 결과 해석의 차이로 이어질 수 있다. 이 연구에서는 세 
가지 서로 다른 측정법을 사용하여 측정한 혈청 칼시토닌 농도 사
이의 일치도를 분석하였다.
방법: 2020년 1-2월에 수집한 104명 환자의 임상 잔여검체를 이용
하여 세 장비로 혈청 칼시토닌 농도를 측정하였다. 모든 장비 간 비
교에 대하여 스피어먼 상관계수, 기울기와 y-절편값을 각각 구하였
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다. 임상적 기준치를 기준으로 한 결과 분류의 일치도를 카파 계수
를 통해 평가하였다.
결과: Cobas e801과 LIAISON, Atellica IM-1600과 LIAISON, Co-
bas e801과 Atellica IM-1600 사이의 스피어먼 상관계수는 각각 
0.77, 0.63, 0.95였다. 칼시토닌 농도 10 pg/mL을 기준으로 한 결과 
분류 간의 카파 계수는 각각 0.81, 0.81, 0.91이었다. 20 pg/mL을 초
과하는 결과값을 제외하고 시행한 분석 결과 스피어먼 상관계수
는 0.39, 0.22, 0.90이었다.
결론: 세 장비로 측정한 칼시토닌 농도 결과값은 특히 임상적 중요 
농도 근처의 낮은 농도의 검체들을 대상으로 한 분석에서 제한적
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